Seminars in Oncology
Volume 35, Issue 5 , Pages 545-552 , October 2008

The Southwest Oncology Group: Progress in Cancer Research

  • Charles A. Coltman Jr

      Affiliations

    • Corresponding Author InformationAddress correspondence to Charles A. Coltman Jr, MD, Southwest Oncology Group Operations Office, 14980 Omicron Dr, San Antonio, TX 78245

References 

  1. Green S, Benedetti J, Crowley J. Clinical trials in oncology: interdisciplinary statistics. London: Chapman & Hall/CRC; 2002;
  2. Smith A, Kopecky KJ, et al. The Southwest Oncology Group specimen tracking system: a web-based tool to support correlative science in a multi-disease cooperative group setting. Clin Trials. 2006;3:214–215
  3. Rothenberg ML, Coltman CA, Fu Kushima M. Summary of a joint meeting between the Southwest Oncology Group and the Japanese Clinical Trials Consortium. J Cancer Res Clin Oncol. 1993;119:564–567
  4. Gandara DR, Kawaguchi T, Crowley JJ, Moon J, Kawahara M, Teramukai S, et al. Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics. J Clin Oncol. 2007;25(Suppl 18):7500
  5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;394:215–224
  6. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: The Selenium and Vitamin E Cancer Prevention Trial Rational and Design. Prostate Cancer Prostatic Dis. 2000;3:145–151
  7. Rivkin SE, Green S, Metch B, Glucksberg H, Gad-el-Mawla N, Constanzi JJ, et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol. 1989;7:1229–1238
  8. Rivkin SE, Green S, Metch B, Jewell WR, Constanzi JJ, Altman SJ, et al. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993;11:1710–1716
  9. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical oophorectomy in premenopausal patients with receptor-positive metastatic breast cancer: an Intergroup Study. J Clin Oncol. 1998;16:994–999
  10. Albain K, Green S, Ravdin P, Cobau C, Levine , Ingle J, et al. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group intergroup trial S8814 (INT-0100). [abstract] Proc Am Soc Clin Oncol. 2001;A94
  11. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, et al. CMF Versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102. [abstract] Proc Am Soc Clin Oncol. 1998;17:A2
  12. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  13. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. The Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13:2936–2943
  14. Macdonald JS, Smalley S, Benedetti J, Estes N, Haller DG, Ajani JA, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction (Results of Intergroup Study INT-0116 (SWOG 9008)). [abstract] Proc Am Soc Clin Oncol. 2000;19:A1
  15. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GM, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730
  16. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205–1209
  17. Lamm DL, Crawford ED, Blumenstein BA, Crissman JD, Montie J, Gottesman J, et al. Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. [abstract] Proc Am Soc Clin Oncol. 1992;A627
  18. Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology. 1995;9:947–952
  19. Crawford ED, Eisenberger MA, McLeod GD, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–424
  20. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866
  21. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically-advanced prostate cancer: a randomized, clinical trial. JAMA. 2006;296:2329–2335
  22. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod GD, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–1042
  23. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  24. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  25. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. Classic Papers Current Comments. 1998;3:145–157
  26. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  27. National Cancer Institute. Concurrent chemoradiation for cervical cancer. 1999;Press Release, February
  28. Schuller DE, Metch B, et al. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope. 1998;98:1205–1211
  29. Al-Sarraf M, LeBlanc M, Gin PGS, Fu K, Cooper J, Vuong T, et al. Superiority of chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (pts) with locally advanced nasopharyngeal cancer (NPC): Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study [abstract]. Proc Am Soc Clin Oncol. 1996;15:A882
  30. Al-Sarraf M, LeBlanc M, Gin PGS, Fu K, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317
  31. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30:457–459
  32. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841–2851
  33. Grever M, Kopecky K, Foucar KM, Head D, Bennett JM, Hutchison RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974–982
  34. List AF, Kopecky KJ, Willman C, Spier C, Dorr R, Flaherty L, et al. Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: a Southwest Oncology Group (SWOG) study. [abstract] Blood. 1998;92:A1281
  35. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995;13:1632–1641
  36. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459–2465
  37. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Mainpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–3218
  38. Ramsey SD, Moinpour CM, Lovalo LC, Grevstad PK, Presant C, Gandara O, et al. An economic analysis alongside a prospective randomized multicenter clinical trial of cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non small cell lung cancer. Lung Cancer. 2000;29(Suppl 2):4
  39. Fabian CJ, Mansfield CM, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease (A Southwest Oncology Group randomized study). Ann Intern Med. 1994;120:903–912
  40. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006
  41. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21–26
  42. Dana BW, Unger J, Fisher RI, et al. A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to Pro-MACE-MOPP (day 1-8) (SWOG 8809). [abstract] Proc Am Soc Clin Oncol. 1998;17:A10
  43. Press OW, LeBlanc M, Lichter A, Wasserman TH, Miller T, Fisher R, et al. A Phase III randomized intergroup trial of subtotal lymphoid irradiation (STLO) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease. [abstract] Blood. 2000;96:575a
  44. Koops HS, Vaglini M, Suciu S, Suclu S, Kroon BBR, Thompson JF, et al Prophylactic isolated limb perfusion for localized high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol. 1998;16:2906–2912
  45. Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 1995;87:1710–1713
  46. Berenson J, Crowley J, Barlogie B, Salmon S. Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients. [abstract] Blood. 1998;92:A1305
  47. Demetri GD, Rankin C, Fletcher C, Benjamm RS, Blanke C, Von Mehren M, et al. Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: Intergroup S0033 early results. [abstract 1651] Proc Am Soc Clin Oncol. 2002;21:413a

 Supported in part by the grants awarded by the following Institutes of the Department of Health and Human Services: National Cancer Institute—CA32102, CA37429 and the National Center for Complementary and Alternative Medicine, CA108964; National Institute of Aging—AG19241; National Eye Institute—EY014418; and National Heart, Lung, and Blood Institute—HL071022.

PII: S0093-7754(08)00164-4

doi: 10.1053/j.seminoncol.2008.07.001

Seminars in Oncology
Volume 35, Issue 5 , Pages 545-552 , October 2008

Article Tools